Effects of monoclonal anti-PcrV antibody on Pseudomonas aeruginosa-induced acute lung injury in a rat model

• Published in: Journal of immune based therapies and vaccines Vol. 1; no. 1; p. 2
• Main Authors: Faure, Karine, Fujimoto, Junichi, Shimabukuro, David W, Ajayi, Temitayo, Shime, Nobuaki, Moriyama, Kiyoshi, Spack, Edward G, Wiener-Kronish, Jeanine P, Sawa, Teiji
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 13.08.2003; BioMed Central
• Subjects: Original Research; Pseudomonas aeruginosa
• ISSN: 1476-8518; 1476-8518
• DOI: 10.1186/1476-8518-1-2

BACKGROUND: The effects of the murine monoclonal anti-PcrV antibody Mab166 on acute lung injury induced by Pseudomonas aeruginosa were analyzed in a rat model. METHODS: Lung injury was induced by the instillation of P. aeruginosa strain PA103 directly into the left lungs of anesthetized rats. One hour after the bacterial instillation, rabbit polyclonal anti-PcrV IgG, murine monoclonal anti-PcrV IgG Mab166 or Mab166 Fab-fragments were administered intratracheally directly into the lungs. The degree of alveolar epithelial injury, amount of lung edema, decrease in oxygenation and extent of lung inflammation by histology were evaluated as independent parameters of acute lung injury. RESULTS: These parameters improved in rats that had received intratracheal instillation of either rabbit polyclonal anti-PcrV IgG, murine monoclonal anti-PcrV IgG Mab166 or Mab166 Fab-fragments in comparison with the control group. CONCLUSION: Mab166 and its Fab fragments have potential as adjuvant therapy for acute lung injury due to P. aeruginosa pneumonia.